Design Therapeutics Inc
$ 13.16
0.30%
20 Apr - close price
- Market Cap 811,607,000 USD
- Current Price $ 13.16
- High / Low $ 13.42 / 12.57
- Stock P/E N/A
- Book Value 3.52
- EPS -1.22
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.31 %
- 52 Week High 13.50
- 52 Week Low 3.10
About
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.
Analyst Target Price
$14.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-17 | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-03-17 | 2024-11-11 | 2024-08-05 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 | 2023-05-09 |
| Reported EPS | -0.27 | -0.3 | -0.34 | -0.31 | -0.24 | -0.23 | -0.21 | -0.2 | -0.21 | -0.28 | -0.36 | -0.35 |
| Estimated EPS | -0.33 | -0.3367 | -0.2967 | -0.28 | -0.2667 | -0.24 | -0.23 | -0.26 | -0.31 | -0.41 | -0.4 | -0.36 |
| Surprise | 0.06 | 0.0367 | -0.0433 | -0.03 | 0.0267 | 0.01 | 0.02 | 0.06 | 0.1 | 0.13 | 0.04 | 0.01 |
| Surprise Percentage | 18.1818% | 10.8999% | -14.5939% | -10.7143% | 10.0112% | 4.1667% | 8.6957% | 23.0769% | 32.2581% | 31.7073% | 10% | 2.7778% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DSGN
2026-04-16 02:40:41
Design Therapeutics (NASDAQ:DSGN) recently hit a new 52-week high of $12.98, trading at $12.9240 with a market capitalization of approximately $776.4 million. The company reported a Q4 EPS of ($0.27), exceeding estimates, and analysts have a "Moderate Buy" consensus with an average price target of $15.20. Institutional investors hold a significant 56.64% stake in the company.
2026-04-08 18:09:01
This article provides an earnings analysis and prediction for DSGN, including upcoming revenue and EPS estimates, historical stock price reactions to earnings reports, and an AI analysis of past performance. It also touches on analyst revisions and investor sentiment surrounding the company's financial outlook.
2026-04-04 10:41:18
This article provides an overview of Design Therapeutics Inc's (DSGN) financial performance, focusing on its profitability and a comparison with competitors. While the company's gross, operating, and net margins are not available, it reports a Return on Equity (ROE) of -30.70%. DSGN, with a market capitalization of $692.58M, is benchmarked against ANRO and ARVN to assess its financial standing within the market.
2026-04-02 17:09:02
Design Therapeutics (NASDAQ:DSGN) reached a new 52-week high of $11.30, trading up approximately 2% on Thursday. The company reported better-than-expected Q1 EPS and has a "Moderate Buy" consensus rating from analysts with an average price target of $15.20. Institutional investors hold a significant portion of the stock, and the company is developing small molecule therapeutic drugs for genetic diseases.
2026-04-02 04:04:00
Design Therapeutics, Inc. announced the appointment of David Shapiro, M.D., to its Board of Directors as a Class III director, effective March 31, 2026. Dr. Shapiro will also serve on the Nominating and Corporate Governance Committee, with his term as director concluding at the company's 2027 annual meeting of stockholders.
2026-04-01 20:39:32
Design Therapeutics, Inc. director David Shapiro has submitted a Form 3, which is an initial statement of beneficial ownership of securities. This filing registers his status as a reporting person with the SEC. The Form 3 indicates no reportable transactions or holdings, meaning it solely serves to acknowledge his director position without disclosing any current share ownership or trading activity.
